Compare DGII & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | SNDX |
|---|---|---|
| Founded | 1985 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.7B |
| IPO Year | N/A | 2016 |
| Metric | DGII | SNDX |
|---|---|---|
| Price | $44.15 | $21.04 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | ★ $46.80 | $36.92 |
| AVG Volume (30 Days) | 295.4K | ★ 1.6M |
| Earning Date | 02-04-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $430,221,000.00 | $111,304,000.00 |
| Revenue This Year | $10.51 | $620.14 |
| Revenue Next Year | $8.01 | $115.42 |
| P/E Ratio | $41.19 | ★ N/A |
| Revenue Growth | 1.46 | ★ 595.65 |
| 52 Week Low | $22.39 | $8.58 |
| 52 Week High | $48.00 | $22.73 |
| Indicator | DGII | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 56.44 | 61.35 |
| Support Level | $43.60 | $19.72 |
| Resistance Level | $44.59 | $22.73 |
| Average True Range (ATR) | 1.23 | 0.88 |
| MACD | -0.34 | -0.08 |
| Stochastic Oscillator | 18.64 | 52.21 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.